Research Papers:
Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion
Metrics: PDF 1704 views | HTML 2061 views | ?
Abstract
Jun Li1, Jing Liu2, Shengnan Li3, Yanli Hao1, Lei Chen3, Xiaoning Zhang1,2
1School of Medicine, Tsinghua University, Beijing 100084, China
2Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, China
3Department of Gynaecology and Obstetrics, PLA Navy General Hospital, Beijing 100037, China
Correspondence to:
Xiaoning Zhang, e-mail: [email protected]
Keywords: siRNA delivery, h-R3, EGFR, siPLK1, targeted delivery
Received: November 07, 2015 Accepted: February 05, 2016 Published: February 13, 2016
ABSTRACT
The major obstacle to developing siRNA delivery is their extracellular and intracellular barriers. Herein, a humanized anti-EGFR monoclonal antibody h-R3 was developed to modify the self-assembled binary complexes (dendriplexes) of PAMAM and siRNA via electrostatic interactions, and two common ligands HSA and EGF were used as a control. Compared to dendriplexes, h-R3/EGF/HSA-dendriplexes showed increased particle size, decreased zeta potentials and lower cytotoxicity. Moreover, h-R3-dendriplexes presented greater cellular uptake and excellent endosomal escape ability in HepG2 cells. Ex vivo fluorescence imaging revealed that h-R3-dendriplexes showed higher targeted delivery and gene expression in the tumors than dendriplexes, HSA-dendriplexes and EGF-dendriplexes, which was in agreement with confocal results of cryosections. Furthermore, h-R3-dendriplexes for siPLK1 delivery indicated efficient gene silencing, potentiated cell growth inhibition and cell apoptosis, and suppressed cellular migration/invasion. These results indicate that h-R3-dendriplexes represent a great potential to be used as efficient targeted siRNA delivery carriers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7368